Christian Apophaticism in Jean-Luc Marion’s early works by Zachhuber, J

“…In this article, I investigate Jean-Luc Marion’s early interpretation of Christian apophaticism with special reference to his reading of Ps.…”

Iris Marion Young and Political Education by Frazer, E

Rapid ovarian transcript changes during the onset of premature ovarian insufficiency by Kaune, H, Montiel, JF, Fenwick, M, Williams, SA

“…Premature ovarian insufficiency (POI) affects 1-3% of women under 40 years of age. …”

In reply: response to Marioni. by Church, D, Talbot, D

The origin of ovarian cancer. by Ahmed, A, Becker, C, Bast, R

The epidemiology of ovarian cancer by Beral, V

“…This paper reviews evidence on the distribution of ovarian cancer in the community and on the characteristics of women who develop ovarian cancer. …”

Androgens are differentially associated with ovarian cancer subtypes in the Ovarian Cancer Cohort Consortium by Ose, J, Poole, E, Schock, H, Lehtinen, M, Arslan, A, Zeleniuch-Jacquotte, A, Visvanathan, K, Helzlsouer, K, Buring, J, Lee, I, Tjønneland, A, Dossus, L, Trichopoulou, A, Masala, G, Onland-Moret, N, Weiderpass, E, Duell, E, Idahl, A, Travis, R, Rinaldi, S, Merritt, M, Trabert, B, Wentzensen, N, Tworoger, S, Kaaks, R, Fortner, R

“…Invasive epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. …”

Gonadotrophins and ovarian cancer risk. by Mohle, J, Whittemore, A, Pike, M, Darby, S

Ovarian cancer risk factor associations by primary anatomic site: The Ovarian Cancer Cohort Consortium by Fortner, RT, Rice, MS, Knutsen, SF, Orlich, MJ, Visvanathan, K, Patel, AV, Gaudet, MM, Tjønneland, A, Kvaskoff, M, Kaaks, R, Trichopolou, A, Pala, V, Onland-Moret, NC, Gram, IT, Amiano, P, Idahl, A, Allen, NE, Weiderpass, E, Poynter, JN, Robien, K, Giles, GG, Milne, RL, Setiawan, VW, Merritt, MA, van den Brandt, PA, Zeleniuch-Jacquotte, A, Arslan, AA, O'Brien, KM, Sandler, DP, Wolk, A, Håkansson, N, Harris, HR, Trabert, B, Wentzensen, N, Tworoger, SS, Schouten, LJ

“…<p>Background: Epithelial ovarian, fallopian tube, and primary peritoneal cancers have shared developmental pathways. …”

Ovarian cancer risk factors by histologic subtype: an analysis from the Ovarian Cancer Cohort Consortium by Wentzensen, N, Poole, E, Trabert, B, White, E, Arslan, A, Patel, A, Setiawan, V, Visvanathan, K, Weiderpass, E, Adami, H, Black, A, Bernstein, L, Brinton, L, Buring, J, Butler, L, Chamosa, S, Clendenen, T, Dossus, L, Fortner, R, Gapstur, S, Gaudet, M, Gram, I, Hartge, P, Hoffman-Bolton, J, Idahl, A, Jones, M, Kaaks, R, Kirsh, V, Koh, W, Lacey, J, Lee, I, Lundin, E, Merritt, M, Onland-Moret, N, Peters, U, Poynter, J, Rinaldi, S, Robien, K, Rohan, T, Sandler, D, Schairer, C, Schouten, L, Sjöholm, L, Sieri, S, Swerdlow, A, Tjonneland, A, Travis, R, Trichopoulou, A, van den Brandt, P, Wilkens, L, Wolk, A, Yang, H, Zeleniuch-Jacquotte, A, Tworoger, S

“…An understanding of the etiologic heterogeneity of ovarian cancer is important for improving prevention, early detection, and therapeutic approaches. …”

Identifying women with undetected ovarian cancer: independent and external validation of QCancer(®) (Ovarian) prediction model. by Collins, G, Altman, D

“…Early identification of ovarian cancer is an unresolved challenge and the predictive value of single symptoms is limited. …”

Ovarian cancer risk factors by tumor aggressiveness: An analysis from the Ovarian Cancer Cohort Consortium by Fortner, RT, Poole, EM, Wentzensen, NA, Trabert, B, White, E, Arslan, AA, Patel, AV, Setiawan, VW, Visvanathan, K, Weiderpass, E, Adami, H-O, Black, A, Bernstein, L, Brinton, LA, Buring, J, Clendenen, TV, Fournier, A, Fraser, G, Gapstur, SM, Gaudet, MM, Giles, GG, Gram, IT, Hartge, P, Hoffman-Bolton, J, Idahl, A, Kaaks, R, Kirsh, VA, Knutsen, S, Koh, W-P, Lacey, JV, Lee, I-M, Lundin, E, Merritt, MA, Milne, RL, Onland-Moret, NC, Peters, U, Poynter, JN, Rinaldi, S, Robien, K, Rohan, T, Sánchez, M-J, Schairer, C, Schouten, LJ, Tjonneland, A, Townsend, MK, Travis, RC, Trichopoulou, A, Van Den Brandt, PA, Vineis, P, Wilkens, L, Wolk, A, Yang, HP, Zeleniuch-Jacquotte, A, Tworoger, SS

“…Ovarian cancer risk factors differ by histotype; however, within subtype, there is substantial variability in outcomes. …”

Hormone replacement therapy and ovarian cancer. by Beral, V, Darby, S, Cuzick, J

Primary ovarian lymphangioma in a child by Sabaratnam, R, Mogotlane, L, Chetty, R

“…The clinical impression was of a cystic ovarian tumor. A right salpingo-oophorectomy was performed. …”

Role of lymphangiogenesis in epithelial ovarian cancer. by Sundar, S, Zhang, H, Brown, P, Manek, S, Han, C, Kaur, K, Charnock, M, Jackson, D, Ganesan, T

“…We investigated the significance of lymphatic count, vascular count and angiogenic growth factors using immunohistochemistry in 108 tumour specimens of epithelial ovarian cancer with antibodies to lymphatic vessel endothelial hyaluronan receptor (LYVE-1), platelet endothelial cell adhesion molecule CD31, vascular endothelial growth factor (VEGF) and thymidine phosphorylase (TP) in epithelial ovarian cancer to understand the pathogenesis of metastasis in ovarian cancer. …”

Targeting tyrosine-kinases in ovarian cancer. by Morotti, M, Becker, C, Menada, M, Ferrero, S

“…INTRODUCTION: Epithelial ovarian cancer (EOC) is the leading cause of gynaecologic cancer death. …”

HORMONE REPLACEMENT THERAPY AND OVARIAN-CANCER by Beral, V, Darby, S, Cuzick, J

A prognostic model for ovarian cancer. by Clark, T, Stewart, M, Altman, D, Gabra, H, Smyth, J

“…About 6000 women in the United Kingdom develop ovarian cancer each year and about two-thirds of the women will die from the disease. …”

Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer--a systematic review and meta-analysis by Siristatidis, C, Sergentanis, T, Kanavidis, P, Trivella, M, Sotiraki, M, Mavromatis, I, Psaltopoulou, T, Skalkidou, A, Petridou, E

“…<br xmlns:etd="http://www.ouls.ox.ac.uk/ora/modsextensions"><strong>Background: </strong> In response to the ongoing debate on the long-term effects of assisted reproduction technologies, such as IVF, we systematically reviewed and meta-analyzed available evidence on the association between controlled ovarian hyperstimulation for IVF and risk of ovarian, endometrial and cervical cancer.…”

Risk of ovarian cancer relapse score: A prognostic algorithm to predict relapse following treatment for advanced ovarian cancer by Rizzuto, I, Stavraka, C, Chatterjee, J, Borley, J, Hopkins, T, Gabra, H, Ghaem-Maghami, S, Huson, L, Blagden, S

“…The strongest predictors of relapse were included into an algorithm, the Risk of Ovarian Cancer Relapse (ROVAR) score. Results: Three hundred fifty-four cases of OC were analyzed to generate the ROVAR score. …”